Biotech | April 04, 2022
Merck expands manufacturing facility in Virginia to increase HPV vaccine supply
Supply increase to help meet growing global demand
Supply increase to help meet growing global demand
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
Highly prestigious award endowed with €500,000 to uphold the United Nations 2030 Agenda
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
Through this new set-up, the company intends to make available, affordable high-quality medical diagnostic imaging equipment across Tier 2, 3, and 4 towns in India
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
WHO’s post EUA inspection found deficiencies in Good Manufacturing Practice at the facility
There is also a strong synergy between Jubilant and Greencure with respect to OTC portfolio which can be explored for R&D, online acceleration and offline distribution
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
Primarily set up to address the Covid-19 emergency, the WHO technology transfer hub has the potential to expand manufacturing capacity for other products as well, including treatments, and target other priorities such as malaria, HIV and cancer
Subscribe To Our Newsletter & Stay Updated
